Steroid 5-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders

By  

Current Pharmaceutical Design, Vol. 17, Iss. 2, 2011-01 ,pp. : 151-167

Bentham Science Publishers

Access to resources Recommend Favorite

Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the 7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 7, Iss. 4, 2007-12 ,pp. : 269-288

Bentham Science Publishers

Access to resources Recommend Favorite

Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review

By  

Current Neuropharmacology, Vol. 13, Iss. 4, 2015-01 ,pp. : 422-434

Bentham Science Publishers

Access to resources Recommend Favorite

-1 Receptor Ligands: Potential in the Treatment of Neuropsychiatric Disorders

By Hayashi T.   Su T-P.  

CNS Drugs, Vol. 18, Iss. 5, 2004-01 ,pp. : 269-284

Adis International

Access to resources Recommend Favorite

A placebo-controlled study of sildenafil effects on cognition in schizophrenia

By Goff Donald   Cather Corinne   Freudenreich Oliver   Henderson David   Evins A.   Culhane Melissa   Walsh Jared  

Psychopharmacology, Vol. 202, Iss. 1-3, 2009-01 ,pp. : 411-417

Springer Publishing Company

Access to resources Recommend Favorite